| 1 | advanced | 14,626 |
| 2 | unresectable | 736 |
| 3 | resectable | 667 |
| 4 | inoperable | 375 |
| 5 | advanced-stage | 234 |
| 6 | nonsquamous | 155 |
| 7 | non-squamous | 152 |
| 8 | advanced/metastatic | 55 |
| 9 | limited-stage | 53 |
| 10 | extensive-stage | 51 |
| 11 | non-resectable | 51 |
| 12 | recurrent/metastatic | 33 |
| 13 | unresected | 33 |
| 14 | nonresectable | 31 |
| 15 | chronic-phase | 27 |
| 16 | hbv-associated | 27 |
| 17 | intermediate-stage | 25 |
| 18 | non-advanced | 25 |
| 19 | nonseminomatous | 22 |
| 20 | hcv-associated | 19 |
| 21 | advanced/recurrent | 18 |
| 22 | liver-only | 17 |
| 23 | non-seminomatous | 17 |
| 24 | noncardia | 17 |
| 25 | non-operable | 16 |
| 26 | colitis-associated | 13 |
| 27 | egfr-positive | 13 |
| 28 | extensive-disease | 13 |
| 29 | alk+ | 12 |
| 30 | intestinal-type | 12 |
| 31 | limited-disease | 11 |
| 32 | bilobar | 10 |
| 33 | far-advanced | 10 |
| 34 | irresectable | 9 |
| 35 | nonbulky | 9 |
| 36 | serosa-positive | 9 |
| 37 | precirrhotic | 8 |
| 38 | smouldering | 8 |
| 39 | telfa | 8 |
| 40 | alk-rearranged | 7 |
| 41 | citracal | 7 |
| 42 | diffuse-type | 7 |
| 43 | n2-3 | 7 |
| 44 | non-exudative | 7 |
| 45 | stage-ii | 7 |
| 46 | gemcitabine-refractory | 6 |
| 47 | supradiaphragmatic | 6 |
| 48 | ct2-4 | 5 |
| 49 | hbv-induced | 5 |
| 50 | kit-positive | 5 |
| 51 | cisplatin-refractory | 4 |
| 52 | gefitinib-insensitive | 4 |
| 53 | h1650 | 4 |
| 54 | h1n1-related | 4 |
| 55 | non-anaplastic | 4 |
| 56 | pathologically-confirmed | 4 |
| 57 | pop≥ | 4 |
| 58 | advanced/unresectable | 3 |
| 59 | e/r-positive | 3 |
| 60 | early-middle | 3 |
| 61 | iiia-pn2 | 3 |
| 62 | intermediate-/high-risk | 3 |
| 63 | mage-a3-positive | 3 |
| 64 | moderate-to-advanced | 3 |
| 65 | m₀ | 3 |
| 66 | non-mlbl | 3 |
| 67 | nonadenocarcinoma | 3 |
| 68 | nongastric | 3 |
| 69 | nonsense-mutation | 3 |
| 70 | pathology-diagnosed | 3 |
| 71 | pt3-pt4 | 3 |
| 72 | rb-associated | 3 |
| 73 | sb/lgs | 3 |
| 74 | unresectable/metastatic | 3 |
| 75 | upper-thoracic | 3 |
| 76 | woodchuck | 3 |
| 77 | 3-brpa-treated | 2 |
| 78 | 769-p | 2 |
| 79 | advanced/aggressive | 2 |
| 80 | advanced/inflammatory | 2 |
| 81 | advanced/inoperable | 2 |
| 82 | ann-arbor | 2 |
| 83 | bells | 2 |
| 84 | cap-resistant | 2 |
| 85 | cimp+ | 2 |
| 86 | ctnm | 2 |
| 87 | d2-resected | 2 |
| 88 | early-to-middle-stage | 2 |
| 89 | facilitated/psychoeducational | 2 |
| 90 | hypocomplementemic | 2 |
| 91 | intermediate-advanced | 2 |
| 92 | intermediate-to-high-risk | 2 |
| 93 | leriche-fontaine | 2 |
| 94 | long-gap | 2 |
| 95 | moderately-advanced | 2 |
| 96 | morula/blastocysts | 2 |
| 97 | non-metastasized | 2 |
| 98 | non-sq | 2 |
| 99 | non-upper | 2 |
| 100 | pb1-f2-deficient | 2 |
| 101 | pikfyveko | 2 |
| 102 | post-necrotic | 2 |
| 103 | r0-resected | 2 |
| 104 | re-positioned | 2 |
| 105 | serosa-negative | 2 |
| 106 | severe-but-stable | 2 |
| 107 | t3-4n0-1m0 | 2 |
| 108 | t4m0 | 2 |
| 109 | ukcccr/anz | 2 |
| 110 | unrespectable | 2 |
| 111 | -heterogeneous | 1 |
| 112 | 0-b | 1 |
| 113 | 12/148 | 1 |
| 114 | 14,899 | 1 |
| 115 | 15,025 | 1 |
| 116 | 2,781-patient | 1 |
| 117 | 3-5fr,5-7cm-long | 1 |
| 118 | 3-hydrazinopyridoxine | 1 |
| 119 | 48,468 | 1 |
| 120 | 6-14-th | 1 |
| 121 | 61,211 | 1 |
| 122 | 74,179 | 1 |
| 123 | 7k-stimulated | 1 |
| 124 | abortions-advanced | 1 |
| 125 | acd-associated | 1 |
| 126 | adma-exposed | 1 |
| 127 | advecting | 1 |
| 128 | alpha-related | 1 |
| 129 | anti-egfr-igg3-triggered | 1 |
| 130 | anti-hsp70s | 1 |
| 131 | anticolorectal | 1 |
| 132 | aom/dss-induced | 1 |
| 133 | ar-derived | 1 |
| 134 | blast-phase | 1 |
| 135 | blm-treated | 1 |
| 136 | borderline-resectable | 1 |
| 137 | braf-defined | 1 |
| 138 | cachexic | 1 |
| 139 | cancer/chemotherapy-associated | 1 |
| 140 | caspase-7-deficient | 1 |
| 141 | caudal/injured | 1 |
| 142 | cd3-negative | 1 |
| 143 | cea-expressing | 1 |
| 144 | cervical-node-positive | 1 |
| 145 | cnb-diagnosed | 1 |
| 146 | corrected-tga | 1 |
| 147 | cox2-positive | 1 |
| 148 | cp-positive | 1 |
| 149 | crkp-positive | 1 |
| 150 | crotonaldehyde-stimulated | 1 |
| 151 | ct-confirmed | 1 |
| 152 | ct1c-4d | 1 |
| 153 | ct2-3 | 1 |
| 154 | ct2-t3 | 1 |
| 155 | ct3bn0m0 | 1 |
| 156 | dehydration-tolerant | 1 |
| 157 | dehydrogenate | 1 |
| 158 | destructs | 1 |
| 159 | diabetes-mellitus-induced | 1 |
| 160 | dodementia | 1 |
| 161 | early-mid | 1 |
| 162 | early-unicellular | 1 |
| 163 | enteric-versus-bladder | 1 |
| 164 | eoe-relevant | 1 |
| 165 | epithelia-derived | 1 |
| 166 | er-positive/unknown | 1 |
| 167 | failed/complicated | 1 |
| 168 | familial-risk | 1 |
| 169 | favorable/intermediate | 1 |
| 170 | fibrocalculus | 1 |
| 171 | fibrolamellar | 1 |
| 172 | gal-3-positive | 1 |
| 173 | gcb-like | 1 |
| 174 | gefitinib-induced | 1 |
| 175 | gem-relapsed | 1 |
| 176 | genetic-driven | 1 |
| 177 | gsk-3β-deficient | 1 |
| 178 | h820 | 1 |
| 179 | half-circumference | 1 |
| 180 | hepatitis-associated | 1 |
| 181 | hep‑g2 | 1 |
| 182 | hk-semi | 1 |
| 183 | hljdd-treated | 1 |
| 184 | htert‑negative | 1 |
| 185 | hyperplastic/mildly | 1 |
| 186 | ic-coated | 1 |
| 187 | iii~iv | 1 |
| 188 | induced*= | 1 |
| 189 | kras-defined | 1 |
| 190 | levodopa-medicated | 1 |
| 191 | lichtman | 1 |
| 192 | locally-advances | 1 |
| 193 | low-/moderate-grade | 1 |
| 194 | md-1483 | 1 |
| 195 | microeconomic | 1 |
| 196 | mid-advanced | 1 |
| 197 | middle/early | 1 |
| 198 | moexipril-containing | 1 |
| 199 | morphine-resistant | 1 |
| 200 | msu-induced | 1 |
| 201 | multireader | 1 |
| 202 | myc-negative | 1 |
| 203 | nasal-type | 1 |
| 204 | nccn/fact | 1 |
| 205 | nh₃-induced | 1 |
| 206 | nmo-igg-positive | 1 |
| 207 | no-diabetic | 1 |
| 208 | non-chemoresistant | 1 |
| 209 | non-end | 1 |
| 210 | non-exsudative | 1 |
| 211 | non-high-grade | 1 |
| 212 | non-keratinizing | 1 |
| 213 | non-polypous | 1 |
| 214 | non-reconstructable | 1 |
| 215 | non-t1-2n0 | 1 |
| 216 | nonkeratinizing/undifferentiated | 1 |
| 217 | nonlobular | 1 |
| 218 | nonrescued | 1 |
| 219 | nonsymptom-driven | 1 |
| 220 | normal/nonneoplastic | 1 |
| 221 | np69 | 1 |
| 222 | oestrogen-receptor-negative | 1 |
| 223 | oncohematological | 1 |
| 224 | outspread | 1 |
| 225 | oxy-cholesterols | 1 |
| 226 | pawr-ko | 1 |
| 227 | pediatric/syndromic | 1 |
| 228 | periannular | 1 |
| 229 | pesticides-associated | 1 |
| 230 | phenylephrine-contracted | 1 |
| 231 | phologistic | 1 |
| 232 | platelet-triggered | 1 |
| 233 | platinum/taxane-refractory/resistant | 1 |
| 234 | pmaci-stimulated | 1 |
| 235 | polyestrous | 1 |
| 236 | post-branchial | 1 |
| 237 | ppargamma-overexpressed | 1 |
| 238 | pre-end | 1 |
| 239 | pre-fermentative | 1 |
| 240 | pre-psychosis | 1 |
| 241 | pre-settlement | 1 |
| 242 | precancereous | 1 |
| 243 | prl-3-expressing | 1 |
| 244 | pseudoginsenoside | 1 |
| 245 | ptmn | 1 |
| 246 | rhsp90α-treated | 1 |
| 247 | rituximab/chemotherapy-relapsed/refractory | 1 |
| 248 | serosa-invading | 1 |
| 249 | smouldering-type | 1 |
| 250 | solo-2 | 1 |
| 251 | stage-ib-ii | 1 |
| 252 | stagei | 1 |
| 253 | stagei-ii | 1 |
| 254 | sub-sea | 1 |
| 255 | t2-t4/n+ | 1 |
| 256 | t3-4n0-2m0 | 1 |
| 257 | ta/ | 1 |
| 258 | tace-eligible | 1 |
| 259 | tfpi-treated | 1 |
| 260 | tfsc-mediated | 1 |
| 261 | tgf-β-positive | 1 |
| 262 | tgfβ1-treated | 1 |
| 263 | trans-ampullary | 1 |
| 264 | tremor-dominant | 1 |
| 265 | trial-g. | 1 |
| 266 | uk/anz | 1 |
| 267 | unresectable-advanced | 1 |
| 268 | unresectable/recurrent | 1 |
| 269 | vhl-deficient | 1 |
| 270 | xad | 1 |
| 271 | ιι-ιιι | 1 |
| 1 | -heterogeneous | 1 |
| 2 | 0-b | 1 |
| 3 | 12/148 | 1 |
| 4 | 14,899 | 1 |
| 5 | 15,025 | 1 |
| 6 | 2,781-patient | 1 |
| 7 | 3-5fr,5-7cm-long | 1 |
| 8 | 3-brpa-treated | 2 |
| 9 | 3-hydrazinopyridoxine | 1 |
| 10 | 48,468 | 1 |
| 11 | 6-14-th | 1 |
| 12 | 61,211 | 1 |
| 13 | 74,179 | 1 |
| 14 | 769-p | 2 |
| 15 | 7k-stimulated | 1 |
| 16 | abortions-advanced | 1 |
| 17 | acd-associated | 1 |
| 18 | adma-exposed | 1 |
| 19 | advanced | 14,626 |
| 20 | advanced-stage | 234 |
| 21 | advanced/aggressive | 2 |
| 22 | advanced/inflammatory | 2 |
| 23 | advanced/inoperable | 2 |
| 24 | advanced/metastatic | 55 |
| 25 | advanced/recurrent | 18 |
| 26 | advanced/unresectable | 3 |
| 27 | advecting | 1 |
| 28 | alk+ | 12 |
| 29 | alk-rearranged | 7 |
| 30 | alpha-related | 1 |
| 31 | ann-arbor | 2 |
| 32 | anti-egfr-igg3-triggered | 1 |
| 33 | anti-hsp70s | 1 |
| 34 | anticolorectal | 1 |
| 35 | aom/dss-induced | 1 |
| 36 | ar-derived | 1 |
| 37 | bells | 2 |
| 38 | bilobar | 10 |
| 39 | blast-phase | 1 |
| 40 | blm-treated | 1 |
| 41 | borderline-resectable | 1 |
| 42 | braf-defined | 1 |
| 43 | cachexic | 1 |
| 44 | cancer/chemotherapy-associated | 1 |
| 45 | cap-resistant | 2 |
| 46 | caspase-7-deficient | 1 |
| 47 | caudal/injured | 1 |
| 48 | cd3-negative | 1 |
| 49 | cea-expressing | 1 |
| 50 | cervical-node-positive | 1 |
| 51 | chronic-phase | 27 |
| 52 | cimp+ | 2 |
| 53 | cisplatin-refractory | 4 |
| 54 | citracal | 7 |
| 55 | cnb-diagnosed | 1 |
| 56 | colitis-associated | 13 |
| 57 | corrected-tga | 1 |
| 58 | cox2-positive | 1 |
| 59 | cp-positive | 1 |
| 60 | crkp-positive | 1 |
| 61 | crotonaldehyde-stimulated | 1 |
| 62 | ct-confirmed | 1 |
| 63 | ct1c-4d | 1 |
| 64 | ct2-3 | 1 |
| 65 | ct2-4 | 5 |
| 66 | ct2-t3 | 1 |
| 67 | ct3bn0m0 | 1 |
| 68 | ctnm | 2 |
| 69 | d2-resected | 2 |
| 70 | dehydration-tolerant | 1 |
| 71 | dehydrogenate | 1 |
| 72 | destructs | 1 |
| 73 | diabetes-mellitus-induced | 1 |
| 74 | diffuse-type | 7 |
| 75 | dodementia | 1 |
| 76 | e/r-positive | 3 |
| 77 | early-mid | 1 |
| 78 | early-middle | 3 |
| 79 | early-to-middle-stage | 2 |
| 80 | early-unicellular | 1 |
| 81 | egfr-positive | 13 |
| 82 | enteric-versus-bladder | 1 |
| 83 | eoe-relevant | 1 |
| 84 | epithelia-derived | 1 |
| 85 | er-positive/unknown | 1 |
| 86 | extensive-disease | 13 |
| 87 | extensive-stage | 51 |
| 88 | facilitated/psychoeducational | 2 |
| 89 | failed/complicated | 1 |
| 90 | familial-risk | 1 |
| 91 | far-advanced | 10 |
| 92 | favorable/intermediate | 1 |
| 93 | fibrocalculus | 1 |
| 94 | fibrolamellar | 1 |
| 95 | gal-3-positive | 1 |
| 96 | gcb-like | 1 |
| 97 | gefitinib-induced | 1 |
| 98 | gefitinib-insensitive | 4 |
| 99 | gem-relapsed | 1 |
| 100 | gemcitabine-refractory | 6 |
| 101 | genetic-driven | 1 |
| 102 | gsk-3β-deficient | 1 |
| 103 | h1650 | 4 |
| 104 | h1n1-related | 4 |
| 105 | h820 | 1 |
| 106 | half-circumference | 1 |
| 107 | hbv-associated | 27 |
| 108 | hbv-induced | 5 |
| 109 | hcv-associated | 19 |
| 110 | hepatitis-associated | 1 |
| 111 | hep‑g2 | 1 |
| 112 | hk-semi | 1 |
| 113 | hljdd-treated | 1 |
| 114 | htert‑negative | 1 |
| 115 | hyperplastic/mildly | 1 |
| 116 | hypocomplementemic | 2 |
| 117 | ic-coated | 1 |
| 118 | iiia-pn2 | 3 |
| 119 | iii~iv | 1 |
| 120 | induced*= | 1 |
| 121 | inoperable | 375 |
| 122 | intermediate-/high-risk | 3 |
| 123 | intermediate-advanced | 2 |
| 124 | intermediate-stage | 25 |
| 125 | intermediate-to-high-risk | 2 |
| 126 | intestinal-type | 12 |
| 127 | irresectable | 9 |
| 128 | kit-positive | 5 |
| 129 | kras-defined | 1 |
| 130 | leriche-fontaine | 2 |
| 131 | levodopa-medicated | 1 |
| 132 | lichtman | 1 |
| 133 | limited-disease | 11 |
| 134 | limited-stage | 53 |
| 135 | liver-only | 17 |
| 136 | locally-advances | 1 |
| 137 | long-gap | 2 |
| 138 | low-/moderate-grade | 1 |
| 139 | mage-a3-positive | 3 |
| 140 | md-1483 | 1 |
| 141 | microeconomic | 1 |
| 142 | mid-advanced | 1 |
| 143 | middle/early | 1 |
| 144 | moderate-to-advanced | 3 |
| 145 | moderately-advanced | 2 |
| 146 | moexipril-containing | 1 |
| 147 | morphine-resistant | 1 |
| 148 | morula/blastocysts | 2 |
| 149 | msu-induced | 1 |
| 150 | multireader | 1 |
| 151 | myc-negative | 1 |
| 152 | m₀ | 3 |
| 153 | n2-3 | 7 |
| 154 | nasal-type | 1 |
| 155 | nccn/fact | 1 |
| 156 | nh₃-induced | 1 |
| 157 | nmo-igg-positive | 1 |
| 158 | no-diabetic | 1 |
| 159 | non-advanced | 25 |
| 160 | non-anaplastic | 4 |
| 161 | non-chemoresistant | 1 |
| 162 | non-end | 1 |
| 163 | non-exsudative | 1 |
| 164 | non-exudative | 7 |
| 165 | non-high-grade | 1 |
| 166 | non-keratinizing | 1 |
| 167 | non-metastasized | 2 |
| 168 | non-mlbl | 3 |
| 169 | non-operable | 16 |
| 170 | non-polypous | 1 |
| 171 | non-reconstructable | 1 |
| 172 | non-resectable | 51 |
| 173 | non-seminomatous | 17 |
| 174 | non-sq | 2 |
| 175 | non-squamous | 152 |
| 176 | non-t1-2n0 | 1 |
| 177 | non-upper | 2 |
| 178 | nonadenocarcinoma | 3 |
| 179 | nonbulky | 9 |
| 180 | noncardia | 17 |
| 181 | nongastric | 3 |
| 182 | nonkeratinizing/undifferentiated | 1 |
| 183 | nonlobular | 1 |
| 184 | nonrescued | 1 |
| 185 | nonresectable | 31 |
| 186 | nonseminomatous | 22 |
| 187 | nonsense-mutation | 3 |
| 188 | nonsquamous | 155 |
| 189 | nonsymptom-driven | 1 |
| 190 | normal/nonneoplastic | 1 |
| 191 | np69 | 1 |
| 192 | oestrogen-receptor-negative | 1 |
| 193 | oncohematological | 1 |
| 194 | outspread | 1 |
| 195 | oxy-cholesterols | 1 |
| 196 | pathologically-confirmed | 4 |
| 197 | pathology-diagnosed | 3 |
| 198 | pawr-ko | 1 |
| 199 | pb1-f2-deficient | 2 |
| 200 | pediatric/syndromic | 1 |
| 201 | periannular | 1 |
| 202 | pesticides-associated | 1 |
| 203 | phenylephrine-contracted | 1 |
| 204 | phologistic | 1 |
| 205 | pikfyveko | 2 |
| 206 | platelet-triggered | 1 |
| 207 | platinum/taxane-refractory/resistant | 1 |
| 208 | pmaci-stimulated | 1 |
| 209 | polyestrous | 1 |
| 210 | pop≥ | 4 |
| 211 | post-branchial | 1 |
| 212 | post-necrotic | 2 |
| 213 | ppargamma-overexpressed | 1 |
| 214 | pre-end | 1 |
| 215 | pre-fermentative | 1 |
| 216 | pre-psychosis | 1 |
| 217 | pre-settlement | 1 |
| 218 | precancereous | 1 |
| 219 | precirrhotic | 8 |
| 220 | prl-3-expressing | 1 |
| 221 | pseudoginsenoside | 1 |
| 222 | pt3-pt4 | 3 |
| 223 | ptmn | 1 |
| 224 | r0-resected | 2 |
| 225 | rb-associated | 3 |
| 226 | re-positioned | 2 |
| 227 | recurrent/metastatic | 33 |
| 228 | resectable | 667 |
| 229 | rhsp90α-treated | 1 |
| 230 | rituximab/chemotherapy-relapsed/refractory | 1 |
| 231 | sb/lgs | 3 |
| 232 | serosa-invading | 1 |
| 233 | serosa-negative | 2 |
| 234 | serosa-positive | 9 |
| 235 | severe-but-stable | 2 |
| 236 | smouldering | 8 |
| 237 | smouldering-type | 1 |
| 238 | solo-2 | 1 |
| 239 | stage-ib-ii | 1 |
| 240 | stage-ii | 7 |
| 241 | stagei | 1 |
| 242 | stagei-ii | 1 |
| 243 | sub-sea | 1 |
| 244 | supradiaphragmatic | 6 |
| 245 | t2-t4/n+ | 1 |
| 246 | t3-4n0-1m0 | 2 |
| 247 | t3-4n0-2m0 | 1 |
| 248 | t4m0 | 2 |
| 249 | ta/ | 1 |
| 250 | tace-eligible | 1 |
| 251 | telfa | 8 |
| 252 | tfpi-treated | 1 |
| 253 | tfsc-mediated | 1 |
| 254 | tgf-β-positive | 1 |
| 255 | tgfβ1-treated | 1 |
| 256 | trans-ampullary | 1 |
| 257 | tremor-dominant | 1 |
| 258 | trial-g. | 1 |
| 259 | uk/anz | 1 |
| 260 | ukcccr/anz | 2 |
| 261 | unresectable | 736 |
| 262 | unresectable-advanced | 1 |
| 263 | unresectable/metastatic | 3 |
| 264 | unresectable/recurrent | 1 |
| 265 | unresected | 33 |
| 266 | unrespectable | 2 |
| 267 | upper-thoracic | 3 |
| 268 | vhl-deficient | 1 |
| 269 | woodchuck | 3 |
| 270 | xad | 1 |
| 271 | ιι-ιιι | 1 |
| 1 | alk+ | 12 |
| 2 | t2-t4/n+ | 1 |
| 3 | cimp+ | 2 |
| 4 | trial-g. | 1 |
| 5 | ta/ | 1 |
| 6 | h820 | 1 |
| 7 | h1650 | 4 |
| 8 | ct3bn0m0 | 1 |
| 9 | t3-4n0-1m0 | 2 |
| 10 | t3-4n0-2m0 | 1 |
| 11 | t4m0 | 2 |
| 12 | non-t1-2n0 | 1 |
| 13 | 61,211 | 1 |
| 14 | solo-2 | 1 |
| 15 | hep‑g2 | 1 |
| 16 | iiia-pn2 | 3 |
| 17 | n2-3 | 7 |
| 18 | ct2-3 | 1 |
| 19 | md-1483 | 1 |
| 20 | ct2-t3 | 1 |
| 21 | ct2-4 | 5 |
| 22 | pt3-pt4 | 3 |
| 23 | 15,025 | 1 |
| 24 | 12/148 | 1 |
| 25 | 48,468 | 1 |
| 26 | np69 | 1 |
| 27 | 74,179 | 1 |
| 28 | 14,899 | 1 |
| 29 | induced*= | 1 |
| 30 | sub-sea | 1 |
| 31 | telfa | 8 |
| 32 | corrected-tga | 1 |
| 33 | noncardia | 17 |
| 34 | dodementia | 1 |
| 35 | nonadenocarcinoma | 3 |
| 36 | 0-b | 1 |
| 37 | upper-thoracic | 3 |
| 38 | hypocomplementemic | 2 |
| 39 | microeconomic | 1 |
| 40 | pediatric/syndromic | 1 |
| 41 | nongastric | 3 |
| 42 | supradiaphragmatic | 6 |
| 43 | advanced/metastatic | 55 |
| 44 | unresectable/metastatic | 3 |
| 45 | recurrent/metastatic | 33 |
| 46 | no-diabetic | 1 |
| 47 | precirrhotic | 8 |
| 48 | post-necrotic | 2 |
| 49 | non-anaplastic | 4 |
| 50 | normal/nonneoplastic | 1 |
| 51 | phologistic | 1 |
| 52 | cachexic | 1 |
| 53 | ct1c-4d | 1 |
| 54 | outspread | 1 |
| 55 | xad | 1 |
| 56 | advanced | 14,626 |
| 57 | mid-advanced | 1 |
| 58 | unresectable-advanced | 1 |
| 59 | intermediate-advanced | 2 |
| 60 | non-advanced | 25 |
| 61 | moderate-to-advanced | 3 |
| 62 | far-advanced | 10 |
| 63 | abortions-advanced | 1 |
| 64 | moderately-advanced | 2 |
| 65 | gefitinib-induced | 1 |
| 66 | aom/dss-induced | 1 |
| 67 | diabetes-mellitus-induced | 1 |
| 68 | msu-induced | 1 |
| 69 | hbv-induced | 5 |
| 70 | nh₃-induced | 1 |
| 71 | alk-rearranged | 7 |
| 72 | ct-confirmed | 1 |
| 73 | pathologically-confirmed | 4 |
| 74 | braf-defined | 1 |
| 75 | kras-defined | 1 |
| 76 | re-positioned | 2 |
| 77 | anti-egfr-igg3-triggered | 1 |
| 78 | platelet-triggered | 1 |
| 79 | caudal/injured | 1 |
| 80 | cnb-diagnosed | 1 |
| 81 | pathology-diagnosed | 3 |
| 82 | adma-exposed | 1 |
| 83 | gem-relapsed | 1 |
| 84 | ppargamma-overexpressed | 1 |
| 85 | levodopa-medicated | 1 |
| 86 | failed/complicated | 1 |
| 87 | tgfβ1-treated | 1 |
| 88 | 3-brpa-treated | 2 |
| 89 | hljdd-treated | 1 |
| 90 | tfpi-treated | 1 |
| 91 | blm-treated | 1 |
| 92 | rhsp90α-treated | 1 |
| 93 | rb-associated | 3 |
| 94 | acd-associated | 1 |
| 95 | pesticides-associated | 1 |
| 96 | colitis-associated | 13 |
| 97 | hepatitis-associated | 1 |
| 98 | hbv-associated | 27 |
| 99 | hcv-associated | 19 |
| 100 | cancer/chemotherapy-associated | 1 |
| 101 | tfsc-mediated | 1 |
| 102 | nonkeratinizing/undifferentiated | 1 |
| 103 | h1n1-related | 4 |
| 104 | alpha-related | 1 |
| 105 | crotonaldehyde-stimulated | 1 |
| 106 | pmaci-stimulated | 1 |
| 107 | 7k-stimulated | 1 |
| 108 | ic-coated | 1 |
| 109 | phenylephrine-contracted | 1 |
| 110 | r0-resected | 2 |
| 111 | d2-resected | 2 |
| 112 | unresected | 33 |
| 113 | nonrescued | 1 |
| 114 | epithelia-derived | 1 |
| 115 | ar-derived | 1 |
| 116 | non-metastasized | 2 |
| 117 | early-mid | 1 |
| 118 | pre-end | 1 |
| 119 | non-end | 1 |
| 120 | half-circumference | 1 |
| 121 | low-/moderate-grade | 1 |
| 122 | non-high-grade | 1 |
| 123 | pseudoginsenoside | 1 |
| 124 | advanced-stage | 234 |
| 125 | limited-stage | 53 |
| 126 | early-to-middle-stage | 2 |
| 127 | intermediate-stage | 25 |
| 128 | extensive-stage | 51 |
| 129 | gcb-like | 1 |
| 130 | non-operable | 16 |
| 131 | inoperable | 375 |
| 132 | advanced/inoperable | 2 |
| 133 | unrespectable | 2 |
| 134 | resectable | 667 |
| 135 | borderline-resectable | 1 |
| 136 | non-resectable | 51 |
| 137 | nonresectable | 31 |
| 138 | unresectable | 736 |
| 139 | advanced/unresectable | 3 |
| 140 | irresectable | 9 |
| 141 | non-reconstructable | 1 |
| 142 | severe-but-stable | 2 |
| 143 | tace-eligible | 1 |
| 144 | early-middle | 3 |
| 145 | leriche-fontaine | 2 |
| 146 | 3-hydrazinopyridoxine | 1 |
| 147 | diffuse-type | 7 |
| 148 | smouldering-type | 1 |
| 149 | intestinal-type | 12 |
| 150 | nasal-type | 1 |
| 151 | limited-disease | 11 |
| 152 | extensive-disease | 13 |
| 153 | chronic-phase | 27 |
| 154 | blast-phase | 1 |
| 155 | favorable/intermediate | 1 |
| 156 | dehydrogenate | 1 |
| 157 | advanced/aggressive | 2 |
| 158 | non-exsudative | 1 |
| 159 | non-exudative | 7 |
| 160 | cd3-negative | 1 |
| 161 | serosa-negative | 2 |
| 162 | myc-negative | 1 |
| 163 | oestrogen-receptor-negative | 1 |
| 164 | htert‑negative | 1 |
| 165 | pre-fermentative | 1 |
| 166 | gefitinib-insensitive | 4 |
| 167 | cox2-positive | 1 |
| 168 | gal-3-positive | 1 |
| 169 | mage-a3-positive | 3 |
| 170 | serosa-positive | 9 |
| 171 | cervical-node-positive | 1 |
| 172 | nmo-igg-positive | 1 |
| 173 | cp-positive | 1 |
| 174 | crkp-positive | 1 |
| 175 | e/r-positive | 3 |
| 176 | egfr-positive | 13 |
| 177 | kit-positive | 5 |
| 178 | tgf-β-positive | 1 |
| 179 | serosa-invading | 1 |
| 180 | moexipril-containing | 1 |
| 181 | smouldering | 8 |
| 182 | prl-3-expressing | 1 |
| 183 | cea-expressing | 1 |
| 184 | advecting | 1 |
| 185 | non-keratinizing | 1 |
| 186 | 3-5fr,5-7cm-long | 1 |
| 187 | 6-14-th | 1 |
| 188 | stagei | 1 |
| 189 | stage-ib-ii | 1 |
| 190 | stage-ii | 7 |
| 191 | stagei-ii | 1 |
| 192 | hk-semi | 1 |
| 193 | woodchuck | 3 |
| 194 | intermediate-to-high-risk | 2 |
| 195 | intermediate-/high-risk | 3 |
| 196 | familial-risk | 1 |
| 197 | citracal | 7 |
| 198 | oncohematological | 1 |
| 199 | post-branchial | 1 |
| 200 | facilitated/psychoeducational | 2 |
| 201 | anticolorectal | 1 |
| 202 | non-mlbl | 3 |
| 203 | ctnm | 2 |
| 204 | lichtman | 1 |
| 205 | genetic-driven | 1 |
| 206 | nonsymptom-driven | 1 |
| 207 | ptmn | 1 |
| 208 | nonsense-mutation | 3 |
| 209 | er-positive/unknown | 1 |
| 210 | pawr-ko | 1 |
| 211 | pikfyveko | 2 |
| 212 | 769-p | 2 |
| 213 | long-gap | 2 |
| 214 | non-sq | 2 |
| 215 | bilobar | 10 |
| 216 | fibrolamellar | 1 |
| 217 | nonlobular | 1 |
| 218 | early-unicellular | 1 |
| 219 | periannular | 1 |
| 220 | multireader | 1 |
| 221 | enteric-versus-bladder | 1 |
| 222 | non-upper | 2 |
| 223 | ann-arbor | 2 |
| 224 | anti-hsp70s | 1 |
| 225 | locally-advances | 1 |
| 226 | sb/lgs | 3 |
| 227 | pre-psychosis | 1 |
| 228 | bells | 2 |
| 229 | oxy-cholesterols | 1 |
| 230 | destructs | 1 |
| 231 | morula/blastocysts | 2 |
| 232 | fibrocalculus | 1 |
| 233 | -heterogeneous | 1 |
| 234 | precancereous | 1 |
| 235 | non-squamous | 152 |
| 236 | nonsquamous | 155 |
| 237 | non-polypous | 1 |
| 238 | polyestrous | 1 |
| 239 | non-seminomatous | 17 |
| 240 | nonseminomatous | 22 |
| 241 | nccn/fact | 1 |
| 242 | tremor-dominant | 1 |
| 243 | dehydration-tolerant | 1 |
| 244 | morphine-resistant | 1 |
| 245 | cap-resistant | 2 |
| 246 | platinum/taxane-refractory/resistant | 1 |
| 247 | non-chemoresistant | 1 |
| 248 | eoe-relevant | 1 |
| 249 | pb1-f2-deficient | 2 |
| 250 | caspase-7-deficient | 1 |
| 251 | vhl-deficient | 1 |
| 252 | gsk-3β-deficient | 1 |
| 253 | 2,781-patient | 1 |
| 254 | pre-settlement | 1 |
| 255 | advanced/recurrent | 18 |
| 256 | unresectable/recurrent | 1 |
| 257 | iii~iv | 1 |
| 258 | nonbulky | 9 |
| 259 | hyperplastic/mildly | 1 |
| 260 | liver-only | 17 |
| 261 | middle/early | 1 |
| 262 | trans-ampullary | 1 |
| 263 | advanced/inflammatory | 2 |
| 264 | gemcitabine-refractory | 6 |
| 265 | cisplatin-refractory | 4 |
| 266 | rituximab/chemotherapy-relapsed/refractory | 1 |
| 267 | uk/anz | 1 |
| 268 | ukcccr/anz | 2 |
| 269 | m₀ | 3 |
| 270 | pop≥ | 4 |
| 271 | ιι-ιιι | 1 |